Form 4: NewAmsterdam Pharma Co Executive Sells Shares
Insider Transaction (Form 4)
Johannes Jacob Pieter Kastelein, Chief Scientific Officer and a Director of NewAmsterdam Pharma Co N.V., sold 50,246 shares of common stock on September 30, 2026 for $25.03 per share.
Summary
- Option exercise/conversion: acquired 50,246 Ordinary Shares on September 30, 2026; holds 119,548 after (Indirect).
- Open-market sale: disposed of 50,246 Ordinary Shares at $25.03 ($1,257,657) on September 30, 2026; holds 69,302 after (Indirect).
- Option exercise/conversion: disposed of 50,246 Option (right to buy) on September 30, 2026; holds 344,983 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,257,657 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Johannes Jacob Pieter Kastelein — Director, Officer (Chief Scientific Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Option exercise/conversion | Ordinary Shares | 50,246 | — | — | 119,548 |
| 2026-09-30 | Open-market sale | Ordinary Shares | 50,246 | $25 | $1.3M | 69,302 |
| 2026-09-30 | Option exercise/conversion | Option (right to buy) | 50,246 | — | — | 344,983 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Option exercise/conversion (50,246 shares) |
| 2026-09-30 | Open-market sale (50,246 shares) |
| 2026-09-30 | Option exercise/conversion (50,246 shares) |
Keywords
insider transaction, Form 4, NAMS, NewAmsterdam Pharma Co N.V., bearish, Johannes Jacob Pieter Kastelein
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.